MX2019014049A - Metodos de fabricacion y uso de inhibidores de pde9. - Google Patents

Metodos de fabricacion y uso de inhibidores de pde9.

Info

Publication number
MX2019014049A
MX2019014049A MX2019014049A MX2019014049A MX2019014049A MX 2019014049 A MX2019014049 A MX 2019014049A MX 2019014049 A MX2019014049 A MX 2019014049A MX 2019014049 A MX2019014049 A MX 2019014049A MX 2019014049 A MX2019014049 A MX 2019014049A
Authority
MX
Mexico
Prior art keywords
making
methods
pde9 inhibitors
pde9
inhibitors
Prior art date
Application number
MX2019014049A
Other languages
English (en)
Inventor
Jun Zhang
Liang Qin
Junhua Zhang
Niels Svenstrup
Jikui Sun
Yuyin Chen
Jianshe Kong
Rujian Ma
Huanming Xiao
Jinxu Sun
Xiao Meng
Fenglai Sun
Jingyang Zhu
Original Assignee
Imara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imara Inc filed Critical Imara Inc
Publication of MX2019014049A publication Critical patent/MX2019014049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a inhibidores de las PDE9, su síntesis y su uso, para el tratamiento de hiperplasia prostática benigna, beta talasemia y enfermedad de células falciformes.
MX2019014049A 2017-05-26 2018-05-25 Metodos de fabricacion y uso de inhibidores de pde9. MX2019014049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511367P 2017-05-26 2017-05-26
PCT/US2018/034566 WO2018218104A1 (en) 2017-05-26 2018-05-25 Methods of making and using pde9 inhibitors

Publications (1)

Publication Number Publication Date
MX2019014049A true MX2019014049A (es) 2020-07-28

Family

ID=64396048

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014049A MX2019014049A (es) 2017-05-26 2018-05-25 Metodos de fabricacion y uso de inhibidores de pde9.
MX2023000191A MX2023000191A (es) 2017-05-26 2019-11-22 Metodos de fabricacion y uso de inhibidores de pde9.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000191A MX2023000191A (es) 2017-05-26 2019-11-22 Metodos de fabricacion y uso de inhibidores de pde9.

Country Status (22)

Country Link
US (2) US11370795B2 (es)
EP (1) EP3630772B1 (es)
JP (1) JP2020527535A (es)
KR (1) KR102627975B1 (es)
CN (2) CN111183140B (es)
BR (1) BR112019024877A2 (es)
CA (1) CA3064004A1 (es)
DK (1) DK3630772T3 (es)
EA (1) EA201992721A1 (es)
ES (1) ES2969895T3 (es)
FI (1) FI3630772T3 (es)
HR (1) HRP20240146T1 (es)
HU (1) HUE065158T2 (es)
IL (1) IL270792B2 (es)
LT (1) LT3630772T (es)
MA (1) MA48793A (es)
MX (2) MX2019014049A (es)
PT (1) PT3630772T (es)
RS (1) RS65143B1 (es)
SI (1) SI3630772T1 (es)
TW (1) TWI791021B (es)
WO (1) WO2018218104A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
IL270792B2 (en) * 2017-05-26 2024-01-01 Imara Inc Methods for the preparation and use of PDE9 inhibitors
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態
CN109734653B (zh) * 2019-02-21 2020-07-14 北京悦康科创医药科技股份有限公司 一种阿加曲班起始原料异构体杂质的拆分方法
WO2020202183A1 (en) * 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
CN114302724A (zh) * 2019-04-05 2022-04-08 伊马拉公司 用于治疗镰状细胞病的pde9抑制剂
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9508554A (pt) 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
SI1368022T1 (sl) 2001-03-02 2007-10-31 Debiopharm Sa Uporaba stekleničke, ki vsebuje raztopino oksaliplatina
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
ME00954B (me) 2007-05-11 2012-06-20 Pfizer Aminoheterociklični spojevi
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
JP5855109B2 (ja) 2010-09-20 2016-02-09 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． イミダゾトリアジノン化合物
CN106905324B (zh) 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
EP2807163B1 (en) * 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
LT2890384T (lt) 2012-08-31 2022-01-10 Taris Biomedical Llc Vaistų pateikimo sistemos ir kraujo vėžio gydymo būdai, apimantys oksaliplatiną
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
IL270792B2 (en) 2017-05-26 2024-01-01 Imara Inc Methods for the preparation and use of PDE9 inhibitors

Also Published As

Publication number Publication date
DK3630772T3 (da) 2024-02-05
HUE065158T2 (hu) 2024-05-28
CA3064004A1 (en) 2018-11-29
KR102627975B1 (ko) 2024-01-19
IL270792B2 (en) 2024-01-01
TW202334156A (zh) 2023-09-01
PT3630772T (pt) 2024-02-05
ES2969895T3 (es) 2024-05-23
JP2020527535A (ja) 2020-09-10
US20230183244A1 (en) 2023-06-15
TWI791021B (zh) 2023-02-01
HRP20240146T1 (hr) 2024-04-12
US11999741B2 (en) 2024-06-04
SI3630772T1 (sl) 2024-05-31
LT3630772T (lt) 2024-02-26
MA48793A (fr) 2020-04-08
WO2018218104A1 (en) 2018-11-29
CN115746003A (zh) 2023-03-07
CN111183140A (zh) 2020-05-19
FI3630772T3 (fi) 2024-01-31
US20200157108A1 (en) 2020-05-21
BR112019024877A2 (pt) 2020-06-09
CN111183140B (zh) 2022-12-02
US11370795B2 (en) 2022-06-28
EP3630772A4 (en) 2021-01-13
EP3630772A1 (en) 2020-04-08
IL270792A (en) 2020-01-30
RS65143B1 (sr) 2024-02-29
EP3630772B1 (en) 2023-11-01
KR20200016891A (ko) 2020-02-17
EA201992721A1 (ru) 2020-09-10
MX2023000191A (es) 2023-02-09
IL270792B1 (en) 2023-09-01
TW201908319A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
MX2023000191A (es) Metodos de fabricacion y uso de inhibidores de pde9.
AU2018236800B2 (en) DNA-PK inhibitors
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
TN2017000507A1 (en) Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
TW201613882A (en) Histone demethylase inhibitors
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
TW201625535A (en) Inhibitors of histone demethylases
CL2017000659A1 (es) Inhibidores de histona desmetilasa
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2016008042A (es) Derivados de imidazopirazinona.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201790604A1 (ru) Ингибиторы гистондеметилазы